Anti-Human CD38 (HB-7) - DyLight® 650
Catalogue Number: C1004-LET
| Manufacturer: | Leinco Technologies, Inc |
| Type: | Monoclonal Primary Antibody - Conjugated |
| Shipping Condition: | Blue Ice |
| Unit(s): | 100 ug, 25 ug, 500 ug |
| Host name: | |
| Clone: | HB-7 |
| Isotype: | |
| Immunogen: | |
| Application: | FC |
Description
Description: CD38 is a type II transmembrane glycoprotein that functions as an adhesion molecule with ectoenzymatic activities that contribute to intracellular calcium mobilization 1,2. Dysregulation is associated with a number of diseases, including HIV, autoimmune, type II diabetes mellitus, osteoporosis, and hematological malignancies such as multiple myeloma (MM) 1, a neoplasm characterized by clonal expansion of malignant plasma cells 2. Because CD38 is strongly and uniformly expressed on myeloma cells, but has limited expression on normal cells, anti-CD38 antibody HB-7 was used to develop an antibody drug conjugate (ADC) capable of killing human myeloma and lymphoma cell lines 3. This ADC is composed of HB-7 conjugated to a chemically modified ricin molecule and is able to block protein synthesis in multiple myeloma cells and in normal bone marrow mononuclear cells. HB-7 was developed by immunizing BALB/c mice with viable cells of the Human Burkitt lymphoma B cell line BJAB 4. The antibody binds to an epitope in the carboxyl terminus of CD38 between residues 273-285, which is also the site of enzyme activity 5. Binding is unaffected by the presence of NAD+ and does not influence CD38 catalytic activity 6.
Additional Text
Concentration
0.2 mg/ml
Antibody Clonality
Monoclonal
Storage Note
This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations